Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$.00X = failed investment, The company is dead.
The reasons for your huge obsession to Ipix affairs has interest for me only because you want my large Ipix investment to fail.
0.0067 LMAO
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
A paid promotion promoting another company. How outstanding.
$0.00755. LMAO.
Great response! Bumps your estimated IQ from 65 to 70.
You do realize “Long IPIX” can mean a single share don’t you?
Your investment is gone and there’s only one person responsible. You.
Free entertainment. His income is tied to your brokerage account. Now that’s some funny shit. Leo’s little bitch.
The guy has a good income
Flatline. This piece of shit is headed to gray markets.
Leo likes his birds bacon wrapped w/ jalapeño. Hoot hoot. 🦉
.006 will soon fall.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
.000’s are here….
Leo’s screwing investors hard. A tube of warming jelly is going for the equivalent of 2500 shares. Soon to be 5000. A million shares will buy you 200 tubes. Some screwing left to be had. Thank you Leo, may I have another… LMAO.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
.000’s are here….
Mods are removed after receiving a warning and continuing to do the very thing they were asked to stop doing
IPIX is dead.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
.000’s are here….
Company history shows Dr. Gold’s efforts will push the price even closer to zero.
Leo’s pumping clown.
Time has told. Leo screwed the pooch.
Bwahahahahaha. Clown.
Wait for the next 3 press releases said the pumping clown. Price has dropped 50% since that ploy was initiated just weeks ago.
What is "hype" is the claim by some few Brilacidin has no value. This is false.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
.000’s are here…. Shareholders are fucked.
Ur Leo’s bitch now. Joe’s Shack. Sloppy. Not first, but second. Next to the pancake house in Ouray. You know the spot. Right under under the falls. It sucks. You know better than most. Eyes wide open.
Decent writing skills my ass. Rather than searching for RICO he should be searching home remedies for chafed holes. I bet if he searches long enough Leo will pop up. How’s that for fucking writing skills? Clowns.
knock knock
.006
If there’s one thing I’ve learned in all my years, you can’t fix stupid. That said, I wish YOU the best of luck.
The Company can't sell in the open market.
IPIX is dead.
.006 -.01 defines the new trading range.
Pumping pigs have been brought to slaughter.
Next stop….
.0000
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
.000’s are here…. Shareholders are fucked.
Who is really selling shares that are under a penny… these are buys
0.0098 LMFAO. Pumping clowns.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
Here come the .000’s…. Shareholders are fucked.
Ah shit. Another bareback horse ride. Giddy up.
I won’t say I didn’t find Leo’s comments worrisome
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
Shareholders are fucked.
Ok. 2 bucks.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
Shareholders are fucked.
Connect the dots
Words from the CEO….
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets…..
The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully…..
Due to the relatively high cost of being a public company in the United States and our limited resources, our Board of Directors may elect to voluntarily deregister our Class A common stock under the Exchange Act and suspend our reporting obligations with the SEC, possibly in combination with beginning to satisfy the alternative reporting standard of the OTC Markets to continue the quotation of our Class A common stock on the OTC Pink…..
Shareholders are fucked.
Yup! Montana has one of the best, if not the best, elk populations in the country. Fishing too. What a great place to live!
Shot a nice 330 bull last week and I’m still cutting up meat after 3 days. 50 lbs of burger to go.